Virus injection for high-risk bladder cancer
Treatments studied
Part of Cancer clinical trials.
This study tests an investigational virus injection given directly into the bladder to treat high-risk bladder cancer that hasn't spread into the muscle. The goal is to see if it's safe and effective in preventing cancer from coming back or getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have high-risk non-muscle invasive bladder cancer (cancer that hasn't spread into the bladder muscle).
- After your most recent bladder surgery or scope exam, there are no visible tumors left, or only small flat areas (carcinoma in situ) remain.
- Your overall health is fairly good (able to do light activities, no severe heart or immune problems).
- You have not had radiation to the bladder, and you've not had certain prior bladder treatments (like chemotherapy or BCG within the last 2 weeks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This study tests a combination of a targeted drug (disitamab vedotin), an immunotherapy drug (PD-1 inhibitor), and radiation therapy as a way to treat bladder cancer without removing the bladder. It is for people whose cancer has grown into the bladder muscle but hasn't spread to other parts of the body, and whose tumor shows high HER2 levels.
This study compares a new combination of chemotherapy drugs delivered directly into the bladder versus standard treatment for people with non-muscle invasive bladder cancer that has returned or not responded to prior therapy. It aims to see if the new treatment helps prevent the cancer from coming back.
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
This trial tests a new drug called KD01, which is given directly into the bladder through a catheter (intravesical instillation) for bladder cancer. It aims to see if the drug is safe and tolerable, and if it may help slow or stop the cancer.
This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.